期刊文献+

西格列汀在糖尿病治疗中的药理作用及临床效果观察

原文传递
导出
摘要 目的:探讨西格列汀在糖尿病治疗中的药理作用,并观察其临床效果。方法:选择2016年1月至2018年1月期间本院收治的68例2型糖尿病患者作为研究对象,随机分为对照组(32例)和观察组(36例)。对照组常规采用饮食控制和二甲双胍治疗,观察组在对照组基础上增加西格列汀治疗,对比分析两组患者治疗前后餐后2h血糖、空腹血糖和糖化血红蛋白指标水平变化。结果:治疗后,观察组空腹血糖(4.65±1.44mmol/L)、餐后2h血糖(7.28±1.36mmol/L)、糖化血红蛋白(6.36±0.95%)指标均显著低于对照组(5.71±1.43mmol/L、8.64±1.34mmol/L、7.45±1.39%),组间差异p<0.05。结论:西格列汀有助于改善2型糖尿病患者的胰岛功能,其应用于临床治疗降糖效果可靠,值得推广借鉴。
作者 张秀彬
出处 《健康之路》 2018年第9期143-143,共1页 Health Way
  • 相关文献

参考文献4

二级参考文献50

  • 1Pumell JQ, Weyer C. Weight effect of current and experimental drug for diabetes mellitus: From promotion to alleviation of obesity [ J ]. Treat Endoennol, 2003,2( 1 ) : 3347.
  • 2Kendall DM, Kin D, Maggs D. Incretin mimeties and dipeptidyl peptidase-lV inhibitors: A review of emerging therapies for type 2 diabetes [J]. Diabetes Teehnol Ther, 2006,8(3):385-396.
  • 3Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011 ] [J]. The Coehrane Collaboration, 2011.
  • 4Available from www. coehrane-handbook.org. Atkins D, Best D, Bfiss PA, et al. Grading quality of evidence and strength of recommendations [J]. BMJ, 2004,328(7454): 1490.
  • 5Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor Sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes [J]. Diabetes Care, 2006,29(12) : 2632-2637.
  • 6Fonseca V, Staels B, Morgan JD 2nd, et al. Efficacy and safety of Sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26- week trim in patients with type 2 diabetes [J]. J Diabetes Complicatians, 2013,27(2) : 177-183.
  • 7Dobs AS, Barry J, Goldstein B J, et al. Efficacy and safety of Sitagliptin added to ongoing mefformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trim in patients with type 2 diabetes [J]. J Diabetes, 2013,5 (1):68-79.
  • 8Mohan V, Yang WY, Son HY, et al. Efficacy and safety of Sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea [J]. Diabetes Res Clin Pract, 2009, 83(1) : 106-116.
  • 9Nonaka K, Kakikawa T, Sato A, et al. Efficacy and safety of Sitagliptin monotherapy in Japanese patients with type 2 diabetes [J]. Diabetes Res Clin Pract, 2008,79(2):291-298.
  • 10Vilsball T, Rosenstock J, Yki-Jarvinen H, et al. Efficacy and safety of Sitagliptin when added to insulin therapy in patients with type 2 diabetes [J]. Diabetes Obes Meta, 2010,12(2): 167-177.

共引文献156

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部